Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Japan Lags Behind in Use of Insulin Pump for Type 1 Diabetics
December 12, 2005
- Breast Cancer Screening Needed in Women in Their 40s: Prof. Ohuchi
December 12, 2005
- Operating Profit Ratios Hold Steady for 4 Leading Wholesalers
December 5, 2005
- Bayer to Increase Investment in Asia-Pacific
December 5, 2005
- REGULATORY NEWS IN BRIEF
December 5, 2005
- R&D NEWS IN BRIEF
December 5, 2005
- Clopidogrel, Silodosin Recommended for Approval
December 5, 2005
- MEDICAL DEVICE NEWS IN BRIEF
December 5, 2005
- Chuikyo Recommends Approval of 4 Ingredients/6 Products
December 5, 2005
- New Medical Materials Should Be Listed 4 Times a Year: Device Industry
December 5, 2005
- Committee Approves Basic Proposal for Next Revision of Med. Fees
December 5, 2005
- 58% of Pharmacists Have Been Asked to Dispense Generics: Survey
December 5, 2005
- Approval of 3 New Products Recommended
December 5, 2005
- Only Stably Supplied Generics Should Be Covered by Insurance: Mr Futagawa
December 5, 2005
- Social Security Spending Needs Further Cuts
December 5, 2005
- Economic Effects of Generics Depend on Their Efficacy: Research Result
December 5, 2005
- MOF's Council Proposes Considerable Cut in Medical Fees
December 5, 2005
- Generic Drug Sales Outpacing the Market: Fuji-keizai
December 5, 2005
- AstraZeneca to Boost Market Share Through 1,700 MR Force: Dr Kato
December 5, 2005
- Generic Substitution Will Become Easier: Mr Yoshida of Towa
December 5, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…